Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19

Abstract

An outbreak of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that started in Wuhan, China, at the end of 2019 has become a global pandemic. Both SARS-CoV-2 and SARS-CoV enter host cells via the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in various human organs. We have reviewed previously published studies on SARS and recent studies on SARS-CoV-2 infection, named coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO), confirming that many other organs besides the lungs are vulnerable to the virus. ACE2 catalyzes angiotensin II conversion to angiotensin-(1–7), and the ACE2/angiotensin-(1–7)/MAS axis counteracts the negative effects of the renin-angiotensin system (RAS), which plays important roles in maintaining the physiological and pathophysiological balance of the body. In addition to the direct viral effects and inflammatory and immune factors associated with COVID-19 pathogenesis, ACE2 downregulation and the imbalance between the RAS and ACE2/angiotensin-(1–7)/MAS after infection may also contribute to multiple organ injury in COVID-19. The SARS-CoV-2 spike glycoprotein, which binds to ACE2, is a potential target for developing specific drugs, antibodies, and vaccines. Restoring the balance between the RAS and ACE2/angiotensin-(1–7)/MAS may help attenuate organ injuries. Graphical abstract SARS-CoV-2 enters lung cells via the ACE2 receptor. The cell-free and macrophage-phagocytosed virus can spread to other organs and infect ACE2-expressing cells at local sites, causing multi-organ injury.

Cited by papers we hold 12

• Blood–brain barrier disruption and sustained systemic inflammation in individuals with long COVID-associated cognitive impairment · 2024
  Corrected
• Bibliometric analysis of the global research status and trends of the association between Vitamin D and infections from 2001 to 2021 · 2022
  Not checked
• Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101) · 2022
  Not checked
• Cannabinoids: Therapeutic Use in Clinical Practice · 2022
  No notice
• Possible kidney-lung cross-talk in COVID-19: in silico modeling of SARS-CoV-2 infection · 2022
  Not checked
• Fulminant hepatic failure in a patient testing re-positive for SARS-CoV-2: a case report · 2021
  Not checked
• Bidirectional relationship between covid-19 and diabetes: Role of renin–angiotensin–aldosterone system and drugs modulating it · 2021
  Not checked
• Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19 · 2021
  No notice
• Incidence, characteristics, and outcome of COVID-19 in patients on liver transplant program: a retrospective study in the north of Iran · 2021
  Not checked
• Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity · 2021
  No notice
• Altered oral and gut microbiota and its association with SARS-CoV-2 viral load in COVID-19 patients during hospitalization · 2021
  Corrected
• Vitamin C—An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19 · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.